Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.2K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

1.8K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
1.8K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

555
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
555
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

4.8K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thermostability Engineering in Therapeutic Antioxidant Enzymes: From Molecular Fundamentals to Oxidative Stress Applications.

International journal of molecular sciences·2026
Same author

IL-6 in Systemic Lupus Erythematosus: At the Intersection of Disease Activity and Cardiovascular Risk.

Journal of clinical medicine·2026
Same author

Molecular Mechanisms and Therapeutic Targets of RNA-Based and Traditional Lipid-Lowering Agents in Residual Cardiovascular Risk: A Scoping Review of Key Directions Towards Future Perspectives.

Biomolecules·2026
Same author

Menopausal Hormone Therapy and Cardiovascular Risk: Current Evidence and Clinical Implications.

Medical sciences (Basel, Switzerland)·2026
Same author

Exploratory Real-World Observations on Pulmonary Function Evolution, HRCT Patterns, and Antifibrotic Escalation in Systemic Sclerosis-Associated Interstitial Lung Disease Treated with Mycophenolate Mofetil.

Journal of clinical medicine·2026
Same author

Subclinical Inflammation in Ischemic Heart Disease and Its Role in the Transition to Heart Failure.

Life (Basel, Switzerland)·2026

Related Experiment Video

Updated: Jan 16, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K

Fetuin-A as a Link Between Dyslipidemia and Cardiovascular Risk in Type 2 Diabetes: A Metabolic Insight for Clinical

Oana Irina Gavril1, Cristina Andreea Adam1, Theodor Constantin Stamate1

  • 1Department of Medical Specialties (I), Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iași, Romania.

Biomedicines
|September 27, 2025
PubMed
Summary

Fetuin-A levels in type 2 diabetes mellitus (T2DM) patients are linked to lipid abnormalities and cardiovascular risk. This suggests fetuin-A may be a useful biomarker for dyslipidemia in diabetic individuals.

Keywords:
cardiovascular riskdiabetes mellitusfetuinlipid profilemetabolic syndromenonalcoholic fatty liver disease

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.7K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
07:05

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: February 23, 2024

3.8K

Related Experiment Videos

Last Updated: Jan 16, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.7K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
07:05

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: February 23, 2024

3.8K

Area of Science:

  • Endocrinology
  • Cardiovascular Medicine
  • Metabolic Research

Background:

  • Fetuin-A, a hepatokine, plays a role in metabolic regulation and is linked to metabolic syndrome and cardiovascular disease.
  • Its precise role in type 2 diabetes mellitus (T2DM) requires further elucidation.
  • Understanding fetuin-A's involvement is crucial for managing diabetic complications.

Purpose of the Study:

  • To investigate the association between fetuin-A levels and metabolic syndrome components in T2DM patients.
  • To explore the relationship between fetuin-A and cardiovascular risk markers like MAFLD, CIMT, and HOMA-IR.
  • To determine fetuin-A's role in dyslipidemia within the T2DM population.

Main Methods:

  • Enrolled 51 T2DM patients not on insulin therapy.
  • Conducted clinical, biochemical, and imaging assessments, including ultrasonography for hepatic steatosis and Doppler ultrasonography for CIMT.
  • Quantified serum fetuin-A using ELISA.

Main Results:

  • Hepatic steatosis correlated with metabolic syndrome, increased CIMT, and dyslipidemia (high total cholesterol, triglycerides; low HDL cholesterol).
  • No direct link was found between fetuin-A and hepatic steatosis.
  • Multivariate analysis indicated fetuin-A levels were significantly affected by total and LDL cholesterol.

Conclusions:

  • Fetuin-A is associated with lipid abnormalities in T2DM patients.
  • Fetuin-A may contribute to cardiovascular risk in this cohort.
  • Fetuin-A shows potential as a biomarker and therapeutic target for dyslipidemia in diabetes.